Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Joaquim Bellmunt(Radboud University Nijmegen), Thomas Powles(St Bartholomew's Hospital), Sanjeev Mariathasan, Yi Shi(Southern Medical University), Peter H. O’Donnell(University of Chicago), Nicole N. Davarpanah(La Roche College), Daniel Castellano(Universidad Complutense de Madrid), Petros Grivas(Fred Hutch Cancer Center), Michiel S. van der Heijden(The Netherlands Cancer Institute), Daniel M. Geynisman(Fox Chase Cancer Center), Maha Hussain(University of Michigan), Jean Hoffman‐Censits(Sidney Kimmel Comprehensive Cancer Center), Siamak Daneshmand, Cora N. Sternberg(Radboud University Nijmegen), Alexandra Drakaki(Columbia University Irving Medical Center), Daniel P. Petrylak(Radboud University Nijmegen), Jonathan E. Rosenberg(Memorial Sloan Kettering Cancer Center), Martin Majchrowicz, Stéphane Oudard(Délégation Paris 5), Jürgen E. Gschwend(TUM Klinikum), Peter Albers(Düsseldorf University Hospital), Hiroyuki Nishiyama(Kyoto University), Jens Bedke, Viraj Degaonkar(La Roche College), Yousef Zakharia(University of Iowa Hospitals and Clinics), Arash Rezazadeh Kalebasty(Norton Healthcare)
The Lancet Oncology
March 14, 2021
10.1016/s1470-2045(21)00004-8
Cited by 411

Related Papers

Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k